Oculis Reports the First Patient Enrollment of OCS-01 in P-III (OPTIMIZE) Trial for the Treatment of Inflammation and Pain Following Cataract Surgery
Shots:
- The first patient has been enrolled in the P-III (OPTIMIZE) trial evaluating the efficacy and safety of OCS-01 (qd) in 240 patients with inflammation and pain following cataract surgery at 25 sites across the US. Additionally, efficacy measures of the trial include the absence of anterior chamber cells on Day 15 and the absence of pain on Day 4
- The P-III trial was based on the results from the P-II trial which met its 1EPs & showed superior efficacy and safety & the results were presented at ASCRS 2020
- Additionally, the therapy is currently being evaluated in an ongoing P-III (DIAMOND) trial for DME with the potential to become the first topical eye drop for a back of the eye disease
Ref: GlobalNewswire | Image: Oculis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
